老年前列腺癌患者使用68Ga-PSMA-11 PET/CT分期:影像前活检是否必要?
该研究纳入100例至少80岁接受68Ga-PSMA-11 PET/CT分期的连续患者,34%在影像前未行确认性活检。B(-)患者较B(+)患者年龄更大、体能状态更差、PSA更高,PET/CT上均见摄取的病灶,骨转移和整体晚期病变比例有升高趋势;在局限或局部晚期病变中B(-)患者较少被转诊接受根治性治疗,但年龄、ECOG体能状态和PSA也是决定治疗方案的其它可能因素。
要点
- 100例≥80岁患者中34例(34%)在68Ga-PSMA-11 PET/CT前未行确认性活检。
- B(-)患者较B(+)患者年龄更大(中位87 vs 82岁,P<0.01)、体能状态更差(P<0.01)、PSA更高(中位57 vs 15.4 ng/mL,P<0.01)。
- B(-)患者PET/CT上均见摄取病灶,骨转移(47.1% vs 28.8%)和整体晚期病变(50% vs 33.3%)比例呈升高趋势。
核心结论
- 真实世界经验显示约三分之一的老年患者在未行影像前确认性活检的情况下被转诊行68Ga-PSMA-11 PET/CT。
- 这些患者可能年龄更大、临床状态更差且PSA水平更高,晚期病变可能更易在其68Ga-PSMA-11 PET/CT图像上被识别。
- 若识别出晚期病变,其活检状态并不妨碍其接受激素治疗。
研究设计与样本
- 纳入100例至少80岁接受分期68Ga-PSMA-11 PET/CT的连续患者。
- 记录每例患者影像前是否行活检、临床参数、PET分期参数及所接受的主要治疗。
主要发现
- 34例(34%)老年患者无影像前活检。
- B(-)患者较B(+)患者年龄更大(中位87 vs 82岁,P<0.01)、体能状态更差(P<0.01)、PSA更高(中位57 vs 15.4 ng/mL,P<0.01)。
- 68Ga-PSMA-11 PET/CT上所有B(-)患者均有摄取病灶,骨转移率(47.1% vs 28.8%)和整体晚期病变率(50% vs 33.3%)较B(+)患者呈升高趋势。
- 在局限性疾病(n=36)或局部晚期疾病(n=25)患者中,B(-)患者较B(+)患者较少被转诊接受根治性治疗(P<0.01)。
- 39例晚期疾病患者中38例接受激素治疗,与活检状态无关;13例有随访数据的B(-)晚期疾病接受激素治疗患者中12例显示生化或影像学缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although prostate-specific membrane antigen (PSMA) PET/CT has been shown valuable for staging biopsy-proven [B(+)] high-risk prostate cancer, elderly patients are occasionally referred for PSMA PET/CT without a preimaging confirming biopsy [B(-)]. The current study evaluated the rate, clinical characteristics, and PET-based stage of elderly B(-) patients and explored whether biopsy status affects therapeutic approach. Methods: One hundred consecutive patients at least 80 y old who underwent staging 68Ga-PSMA-11 PET/CT were included. For each patient, we documented whether preimaging biopsy was performed, the clinical parameters, the PET-based staging parameters, and the primary therapy received. Results: Thirty-four (34%) of the elderly patients included in the study had no preimaging biopsy. Compared with B(+) patients, B(-) patients were older (median age, 87 vs. 82 y; P < 0.01), with worse performance status (P < 0.01) and higher prostate-specific antigen (PSA) levels (median, 57 vs. 15.4 ng/mL; P < 0.01). On 68Ga-PSMA-11 PET/CT, all B(-) patients had avid disease, with trends toward higher rates of bone metastases (47.1% vs. 28.8%) and overall advanced disease (50% vs. 33.3%) than in B(+) patients. Among patients with localized (n = 36) or locally advanced (n = 25) disease, B(-) patients were less commonly referred than B(+) patients for definitive therapies (P < 0.01). However, higher age, Eastern Cooperative Oncology Group performance status, and PSA were other probable factors determining their therapeutic approach. Among 39 patients with advanced disease, 38 received hormonal therapy irrespective of their biopsy status. Among B(-) patients with advanced disease who were referred for hormonal therapy, 12 of 13 with follow-up data showed a biochemical or imaging-based response. Conclusion: Real-life experience with 68Ga-PSMA-11 PET/CT indicates that around one third of elderly patients are referred for imaging without a preimaging confirming biopsy. These patients are likely to be older, with a worse clinical status and higher PSA levels. Advanced disease might be more likely to be identified on their 68Ga-PSMA-11 PET/CT images, and if it is, their biopsy status does not preclude them from receiving hormonal therapy.
引用
- Kesler M, Cohen D, Levine C, et al. Staging Prostate Cancer with 68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative? J Nucl Med. 2023. PMID: 37116912. doi:10.2967/jnumed.122.265371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。